Teva Pharmaceuticals
TEVA
705 hedge funds and large institutions have $16.7B invested in Teva Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 264 increasing their positions, 297 reducing their positions, and 72 closing their positions.
16% more call options, than puts
Call options by funds: $357M | Put options by funds: $307M
1.24% more ownership
Funds ownership: 44.92% → 46.16% (+1.2%)
0% more capital invested
Capital invested by funds: $16.6B → $16.7B (+$80.5M)
5% less funds holding
Funds holding: 744 → 705 (-39)
9% less funds holding in top 10
Funds holding in top 10: 32 → 29 (-3)
11% less repeat investments, than reductions
Existing positions increased: 264 | Existing positions reduced: 297
43% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 72
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$210M |
| 2 |
SFM
Soros Fund Management
New York
|
+$141M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$119M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$87.3M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$79.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Abrams Capital Management
Boston,
Massachusetts
|
-$100M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$87.2M |
| 3 |
HCM
Highfields Capital Management
Boston,
Massachusetts
|
-$60.4M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$48.7M |
| 5 |
SIC
Sky Investment Counsel
Toronto,
Ontario, Canada
|
-$48.1M |
TEVA Hedge Fund Activity: Q3 2013 in Review
705 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2013, worth a combined $16.7B — up 0.49% from $16.6B a quarter earlier.
Sellers outnumbered buyers: 72 funds closed out of TEVA and 41 opened new positions — a net loss of 31 holders — while 297 trimmed existing stakes and 264 added.
The largest buyer was Fidelity Investments, adding an estimated $210M. The largest seller was Abrams Capital Management, exiting entirely with an estimated $100M sold.
- 705 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2013, down from 744 in Q2 2013.
- Funds reported $16.7B of Teva Pharmaceuticals stock for Q3 2013, up 0.49% quarter-over-quarter.
- 41 funds opened new Teva Pharmaceuticals positions in Q3 2013 and 72 closed out, a net change of -31 holders.
- The largest Teva Pharmaceuticals buyer in Q3 2013 was Fidelity Investments, an estimated $210M added.
- The largest Teva Pharmaceuticals seller in Q3 2013 was Abrams Capital Management, an estimated $100M sold.
Based on aggregated 13F filings for Q3 2013.